Torben Frøstrup Hansen

Medicine & Life Sciences

1. Adenocarcinoma 7%
2. Angiogenesis Inhibitors 10%
3. Bevacizumab 33%
4. Biliary Tract Neoplasms 18%
5. Biomarkers 20%
6. Bronchoalveolar Lavage 9%
7. Capecitabine 24%
8. Chemoradiotherapy 9%
9. Circulating MicroRNA 15%
10. Circulating Tumor DNA 32%
11. Colonic Neoplasms 74%
12. Colorectal Neoplasms 100%
13. Combination Drug Therapy 9%
14. Confidence Intervals 12%
15. Denmark 8%
16. Disease-Free Survival 7%
17. DNA 13%
18. DNA Mismatch Repair 7%
19. Drug Therapy 35%
20. Epidermal Growth Factor 16%
21. Exons 7%
22. gemcitabine 6%
23. Genes 12%
24. Homeobox Genes 8%
25. Immunotherapy 9%
26. Lung Neoplasms 8%
27. MicroRNAs 72%
28. Microsatellite Instability 10%
29. Microvessels 14%
30. Mutation 8%
31. Natural Killer Cells 11%
32. Neoplasms 40%
33. Neuropeptide Y 6%
34. Oxaliplatin 33%
35. Panitumumab 12%
36. Polymerase Chain Reaction 8%
37. Population 10%
38. Progression-Free Survival 18%
39. Prostatic Neoplasms 14%
40. Rectal Neoplasms 31%
41. Recurrence 11%
42. regorafenib 6%
43. Single Nucleotide Polymorphism 20%
44. Survival 24%
45. Systematic Reviews 6%
46. Therapeutics 18%
47. Tumor-Infiltrating Lymphocytes 10%
48. Vascular Endothelial Growth Factor A 20%
49. Vascular Endothelial Growth Factor Receptor-2 11%
50. XELOX 9%